Breaking Finance News

Alcobra Ltd (NASDAQ:ADHD) has been downgraded to Market Perform in a report by Oppenheimer Holdings Inc. today.

Oppenheimer Holdings Inc. has downgraded Alcobra Ltd (NASDAQ:ADHD) to Market Perform in a report released on Thursday September 29, 2016.

On 09/12/2016, WBB Securities released a statement about Alcobra Ltd (NASDAQ:ADHD) reduced the target price from $5.00 to $4.00. At the time, this indicated a possible downside of -0.17%.

Having a price of $2.03, Alcobra Ltd (NASDAQ:ADHD) traded -53.64% lower on the day. The last closing price is down -52.77% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. ADHD has recorded a 50-day moving average of $4.83 and a 200-day moving average of $4.53. Trade Volume was up over the average, with 1,624,270 shares of ADHD changing hands over the typical 92,709

Recent Performance Chart

Alcobra Ltd (NASDAQ:ADHD)

Alcobra Ltd has a with a one year low of $2.00 and a one year high of $8.78 ADHD’s total market value is presently $0.

A total of 7 firms have issued a report on the stock. Three brokerages rating the company a strong buy, three analysts rating the company a buy, 0 brokers rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 analysts rating the company a sell with a one year target of $12.71.

More About Alcobra Ltd (NASDAQ:ADHD)

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.